MARATTO

article · The Egyptian Journal of Haematology

Irisin in myelodysplastic syndromes: connecting inflammation, oncogenesis, and atherogenesis

2024Open accessZagazig University

Abstract

Objective This study aimed to measure irisin level and carotid intima-media thickness (CIMT), and, to unravel their correlations with other variables in patients with myelodysplastic syndromes (MDS). Background Multiple components of the marrow environment and of the MDS cell hierarchy itself can contribute to an inflammatory state which can influence MDS emergence, propagation, and evolution. Irisin is an adipomyokine that is involved.in.the.regulation.of.metabolic.processes.and.also.influences.processes.related.to.inflammation including cancer. Atherosclerosis is a chronic inflammatory vascular disease driven by traditional and nontraditional risk factors. Patients and methods This case–control study was carried out on 40 MDS patients and 40 age-matched and sex-matched healthy controls. Serum irisin level and CIMT were measured. Results The median irisin level and high-density lipoproteins were significantly lower in MDS patients compared with controls whereas CIMT, fasting blood glucose, 2 h postprandial blood sugar, hemoglobin A1c, homeostatic model assessment of insulin resistance, triglycerides, homocysteine, and high sensitive C-reactive protein were significantly higher in patients than controls. Conclusion Irisin level is significantly lower in patients with MDS where as CIMT is significantly higher in MDS patients compared to controls.

Research topics

  • Adipose Tissue and Metabolism
  • Mitochondrial Function and Pathology
  • Adipokines, Inflammation, and Metabolic Diseases

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.4103/ejh.ejh_93_23

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.